Cell-based Assays Market Size, Share & Trends Analysis Report By Products & Services (Reagents, Assay Kits), By Application (Basic Research, Drug Discovery), By End Use, By Region, And Segment Forecasts, 2024 - 2030

Cell-based Assays Market Size & Trends

The global cell-based assays market size was valued at USD 18.7 billion in 2023 and is projected to grow at a CAGR of 8.8% from 2024 to 2030. The industry is experiencing significant growth opportunities as a result of factors such as the increasing demand for drug discovery, the growing necessity for research in biotechnology, and the rising prevalence of infectious diseases, cancer, autoimmune disorders, and genetic conditions.

The forecast period anticipates substantial growth in the global cell-based assays market due to the increasing emphasis on drug development worldwide. Cell-based assays are crucial in the initial stages of drug discovery as they facilitate the assessment of compound effectiveness, toxicity, and safety profiles. The persistent requirement for novel drugs, joined with the expanding pharmaceutical and biotechnology sectors, drives the demand for cell-based assays.

Cell-based assays are widely utilized in the drug discovery phase to confirm the effectiveness of potential drug candidates. These assays are also used for lead profiling, cellular signaling, and toxicity assessment. Accordingly, the industry is highly competitive, with key players providing a variety of products and services such as reagents, assay kits, instruments, and contract research services. Continued innovation, product development, strategic partnerships, and the growing use of cell-based assays in different research areas are anticipated to fuel market growth in the future.

The drug discovery sector is expected to experience significant growth in the market, largely due to the increase in R&D funding from biopharmaceutical firms and government, increasing focus on personalized medicine, and the expansion of pharmaceutical and biotechnology industries. Furthermore, the escalating occurrence of chronic illnesses such as cancer, osteoarthritis, cardiovascular diseases, and diabetes is driving the need for cell-based assays in the search for innovative drug developments, thus playing a crucial role in the market's expansion.

Products & Services Insights

Assay kits dominated the market and accounted for revenue share of 40.4% in 2023. The segment is expected to continue growing rapidly, owing to its effectiveness in a range of biopharmaceutical applications. These kits are essential for analyzing different sides of cellular behavior, including cell cycle advancement, movement, and infiltration, as well as for assessing the levels of crucial cell components that are commonly employed to assess cell viability and their reaction to various stimuli.

Reagents segment is expected to witness rapid growth with a CAGR of 9.1% over the forecast period. Reagents serve the purpose of analyzing multiple properties of living cells and encompass a range of assays including cell growth and differentiation, apoptosis, and signal transduction assays. Due to their heavy usage by numerous biopharmaceutical and biotechnological companies in the industry, there is a significant demand for consumable products for the development and production of cells.

Application Insights

Drug discovery accounted led the market in 2023 with a revenue share of 40.0% owing to the increasing need for innovative therapies, intensifying competition for FDA approvals, and substantial investments in research and development. The sector is also fueled by government and biopharmaceutical companies' initiatives, introduction of novel medications, and rising prevalence of chronic diseases, such as cancer, cardiovascular disorders, and diabetes.

Basic research applications are expected to witness the fastest growth of 9.3% between 2024 and 2030. Cell-based assays enable researchers to study the effects of drugs, compounds, and environmental factors on specific cell types, providing insights into biological pathways and potential therapeutic targets. The growing prevalence of chronic diseases, such as cancer and neurodegenerative disorders, has driven the need for basic research using cell-based assays to uncover disease pathogenesis and develop novel treatment strategies.

End Use Insights

Pharmaceutical & biotechnology companies segment dominated the market in 2023 with a revenue share of 50.7%. Revenue generated in the segment is expected to rise in the coming years, driven by their advantages in biotech and pharma companies. These industries need accurate and high-throughput screening techniques to evaluate cells' toxicity and mobility. The growing focus on personalized medicine and targeted therapies is also driving demand for cell-based assays, which are essential for biotechnology and pharmaceutical advancements.

Academic & research institutes are projected to be the fastest-growing end user segment over the forecast period, registering a CAGR of 10.0%. The academic and research institutes end use segment is projected to experience the highest CAGR in the upcoming forecast period. This growth is primarily driven by the increasing utilization of these assays for cell-based research and the development of innovative assay-based diagnostics. Academic & Research Institutes continuously trying to make inventions in the cell-based assays to make it even better.

Regional Insights

North America cell-based assays market dominated the global cell-based assays market in 2023, capturing a significant share of over 47.7% of the total revenue. This region is expected to continue its expansion at a consistent growth rate, firmly holding its position as the leader throughout the forecast period. The remarkable growth of the market in North America can be primarily attributed to the collaborative efforts between academic research institutes and pharmaceutical companies, which have conducted extensive research in various research institutes across the region.

U.S. Cell-based Assays Market Trends

The cell-based assays market in the U.S. dominated the market with a share of 84.3% in 2023, driven by the high incidence of chronic diseases such as cancer, diabetes, arthritis, and cardiovascular disease. The growing focus on personalized medicine and the booming biopharmaceutical and biotechnology industries in the region are also contributing to the market's growth.

Europe Cell-based Assays Market Trends

Europe cell-based assays market was identified as a lucrative region in this industry. Market growth in the region is fueled by various factors including rising research endeavors, a robust pharmaceutical sector, high incidence of chronic illnesses, advancements in technology, government support, presence of key market players, and the shift towards personalized medicine. With these factors in play, the market is projected to grow even more in the region.

Cell-based assays market in the UK is expected to grow rapidly over the forecast period due to the demand for drug discovery and development and global market expansion. The presence of numerous pharmaceutical and biotech companies drives adoption for drug discovery. The UK's well-established academic and research institutes actively conduct basic research using cell-based assays. The government's Life Sciences Sector Deal and skilled researchers with advanced infrastructure make the UK an attractive location for cell-based assay research and development.

Asia Pacific Cell-based Assays Market Trends

The cell-based assays market in the Asia Pacific region is set to experience notable growth, driven by rapid infrastructural development and increased R&D investments by governments. Research studies sponsored by pharmaceutical giants are contributing to the rising demand for cell-based assays across various applications. Furthermore, government initiatives for infrastructural development are boosting regional growth, along with the growing demand for drug development in developing countries.

China cell-based assays market held a substantial market share in 2023 owing to expansion in China's biotechnology and pharmaceutical industries, leading to an increased need for cell-based assays. These assays play a vital role in the process of drug discovery and development.

Key Cell-based Assays Company Insights

Some of the key companies in the cell-based assays market include Bio-Rad Laboratories, Inc.; Corning Incorporated; Merck KGaA; Lonza Group AG; Charles River Laboratories; and Becton, Dickinson and Company (BD). Prominent market participants are focusing on increasing customer base using mergers, acquisitions, and partnerships with other major companies.

• Bio-Rad focuses on the development and production of a vast array of products designed for the life science research and clinical diagnostic markets. As the company specializes in in-vitro diagnostics supplies on a global scale, it utilizes a diverse range of technologies to deliver crucial clinical information in the markets of blood transfusion, diabetes monitoring, autoimmune diseases, and infectious disease testing.

• Corning Incorporated is dedicated to the production and development of specialty glass, ceramics, and related materials. With a focus on advanced optics, the company cater primarily to industrial and scientific sectors, providing cutting-edge solutions for various applications.

Recent Development

• In April 2024, BD India launched the BD Vacutainer UltraTouch Push Button Blood Collection Set to minimize patient pain and discomfort. The device featured BD RightGauge and PentaPoint technologies, reducing insertion pain and needle injury risks.

• In March 2024, Lonza acquired the Genentech manufacturing facility in Vacaville, U.S., from F. Hoffmann-La Roche Ltd. (Roche Holdings AG) through an agreement. The acquisition augmented Lonza's large-scale biologics manufacturing capacity, making it one of the largest biologics manufacturing facilities globally.

Cell-based Assays Market Report Scope

Global Cell-based Assays Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global cell-based assays market report based on products & services, application, end use, and region.

• Products & Services Outlook (Revenue, USD Million, 2018 - 2030)

  • Reagents

  • Assay Kits

    • Cell Growth Assays

    • Reporter Gene Assays

    • Cell Death Assays

    • Second Messenger Assays

  • Microplates

  • Probes & Labels

  • Instruments & Software

  • Cell Lines

    • Primary Cell Lines

    • Stem Cell Lines

    • Immortalized Cell Lines

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Basic Research

  • Drug Discovery

  • Other Applications

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic & Research Institutes

  • Contract Research Organizations (CROs)

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait